Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO

Swati Biswas, Neelam Tankhiwale, Amanda Blackford, Angelica M Gutierrez Barrera, Kaylene Ready, Karen Lu, Christopher I. Amos, Giovanni Parmigiani, Banu Arun

Research output: Contribution to journalArticle

Abstract

The BRCAPRO model estimates carrier probabilities for the BRCA1 and BRCA2 genes, and was recently enhanced to use estrogen receptor (ER) and progesterone receptor (PR) status of breast cancer. No independent assessment of the added value of these markers exists. Moreover, earlier versions of BRCAPRO did not use human epidermal growth factor receptor 2 (Her-2/neu) status of breast cancer. Here, we incorporate Her-2/neu in BRCAPRO and validate all the markers. We trained the enhanced model on 406 germline tested individuals, and validated on a separate clinical cohort of 796 individuals for whom test results and family history are available. For model-building, we estimated joint probabilities of ER, PR, and Her-2/neu status for carriers and non-carriers of BRCA1/2 mutations. For validation, we obtained BRCAPRO predictions with and without markers. We calculated area under the receiver operating characteristic curve (AUC), sensitivity, specificity, predictive values, and correct reclassification rates. The AUC for predicting BRCA1 status among individuals who are carriers of at least one mutation improved when ER and PR were used. The AUC for predicting the presence of either mutation improved when Her-2/neu was added. Use of markers also produced highly significant correct reclassification improvements in both cases. Breast tumor markers are useful for prediction of BRCA1/2 mutation status. ER and PR improve discrimination between BRCA1 and BRCA2 mutation carriers while Her-2/neu helps discriminate between carriers and non-carriers, particularly among women who are ER positive and Her-2/neu negative. These results support the use of the enhanced version of BRCAPRO in clinical settings.

Original languageEnglish (US)
Pages (from-to)347-355
Number of pages9
JournalBreast Cancer Research and Treatment
Volume133
Issue number1
DOIs
StatePublished - May 2012
Externally publishedYes

Fingerprint

Tumor Biomarkers
Estrogen Receptors
Progesterone Receptors
Breast Neoplasms
Mutation
Area Under Curve
BRCA2 Gene
BRCA1 Gene
ROC Curve
Sensitivity and Specificity

Keywords

  • BayesMendel
  • BRCA1
  • BRCA2
  • BRCAPRO
  • CancerGene
  • ER
  • Genetic risk
  • Her-2/neu
  • PR
  • Validation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Biswas, S., Tankhiwale, N., Blackford, A., Barrera, A. M. G., Ready, K., Lu, K., ... Arun, B. (2012). Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Research and Treatment, 133(1), 347-355. https://doi.org/10.1007/s10549-012-1958-z

Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. / Biswas, Swati; Tankhiwale, Neelam; Blackford, Amanda; Barrera, Angelica M Gutierrez; Ready, Kaylene; Lu, Karen; Amos, Christopher I.; Parmigiani, Giovanni; Arun, Banu.

In: Breast Cancer Research and Treatment, Vol. 133, No. 1, 05.2012, p. 347-355.

Research output: Contribution to journalArticle

Biswas, S, Tankhiwale, N, Blackford, A, Barrera, AMG, Ready, K, Lu, K, Amos, CI, Parmigiani, G & Arun, B 2012, 'Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO', Breast Cancer Research and Treatment, vol. 133, no. 1, pp. 347-355. https://doi.org/10.1007/s10549-012-1958-z
Biswas, Swati ; Tankhiwale, Neelam ; Blackford, Amanda ; Barrera, Angelica M Gutierrez ; Ready, Kaylene ; Lu, Karen ; Amos, Christopher I. ; Parmigiani, Giovanni ; Arun, Banu. / Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. In: Breast Cancer Research and Treatment. 2012 ; Vol. 133, No. 1. pp. 347-355.
@article{5a24384c5c1648be8d0a71910f9c920a,
title = "Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO",
abstract = "The BRCAPRO model estimates carrier probabilities for the BRCA1 and BRCA2 genes, and was recently enhanced to use estrogen receptor (ER) and progesterone receptor (PR) status of breast cancer. No independent assessment of the added value of these markers exists. Moreover, earlier versions of BRCAPRO did not use human epidermal growth factor receptor 2 (Her-2/neu) status of breast cancer. Here, we incorporate Her-2/neu in BRCAPRO and validate all the markers. We trained the enhanced model on 406 germline tested individuals, and validated on a separate clinical cohort of 796 individuals for whom test results and family history are available. For model-building, we estimated joint probabilities of ER, PR, and Her-2/neu status for carriers and non-carriers of BRCA1/2 mutations. For validation, we obtained BRCAPRO predictions with and without markers. We calculated area under the receiver operating characteristic curve (AUC), sensitivity, specificity, predictive values, and correct reclassification rates. The AUC for predicting BRCA1 status among individuals who are carriers of at least one mutation improved when ER and PR were used. The AUC for predicting the presence of either mutation improved when Her-2/neu was added. Use of markers also produced highly significant correct reclassification improvements in both cases. Breast tumor markers are useful for prediction of BRCA1/2 mutation status. ER and PR improve discrimination between BRCA1 and BRCA2 mutation carriers while Her-2/neu helps discriminate between carriers and non-carriers, particularly among women who are ER positive and Her-2/neu negative. These results support the use of the enhanced version of BRCAPRO in clinical settings.",
keywords = "BayesMendel, BRCA1, BRCA2, BRCAPRO, CancerGene, ER, Genetic risk, Her-2/neu, PR, Validation",
author = "Swati Biswas and Neelam Tankhiwale and Amanda Blackford and Barrera, {Angelica M Gutierrez} and Kaylene Ready and Karen Lu and Amos, {Christopher I.} and Giovanni Parmigiani and Banu Arun",
year = "2012",
month = "5",
doi = "10.1007/s10549-012-1958-z",
language = "English (US)",
volume = "133",
pages = "347--355",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO

AU - Biswas, Swati

AU - Tankhiwale, Neelam

AU - Blackford, Amanda

AU - Barrera, Angelica M Gutierrez

AU - Ready, Kaylene

AU - Lu, Karen

AU - Amos, Christopher I.

AU - Parmigiani, Giovanni

AU - Arun, Banu

PY - 2012/5

Y1 - 2012/5

N2 - The BRCAPRO model estimates carrier probabilities for the BRCA1 and BRCA2 genes, and was recently enhanced to use estrogen receptor (ER) and progesterone receptor (PR) status of breast cancer. No independent assessment of the added value of these markers exists. Moreover, earlier versions of BRCAPRO did not use human epidermal growth factor receptor 2 (Her-2/neu) status of breast cancer. Here, we incorporate Her-2/neu in BRCAPRO and validate all the markers. We trained the enhanced model on 406 germline tested individuals, and validated on a separate clinical cohort of 796 individuals for whom test results and family history are available. For model-building, we estimated joint probabilities of ER, PR, and Her-2/neu status for carriers and non-carriers of BRCA1/2 mutations. For validation, we obtained BRCAPRO predictions with and without markers. We calculated area under the receiver operating characteristic curve (AUC), sensitivity, specificity, predictive values, and correct reclassification rates. The AUC for predicting BRCA1 status among individuals who are carriers of at least one mutation improved when ER and PR were used. The AUC for predicting the presence of either mutation improved when Her-2/neu was added. Use of markers also produced highly significant correct reclassification improvements in both cases. Breast tumor markers are useful for prediction of BRCA1/2 mutation status. ER and PR improve discrimination between BRCA1 and BRCA2 mutation carriers while Her-2/neu helps discriminate between carriers and non-carriers, particularly among women who are ER positive and Her-2/neu negative. These results support the use of the enhanced version of BRCAPRO in clinical settings.

AB - The BRCAPRO model estimates carrier probabilities for the BRCA1 and BRCA2 genes, and was recently enhanced to use estrogen receptor (ER) and progesterone receptor (PR) status of breast cancer. No independent assessment of the added value of these markers exists. Moreover, earlier versions of BRCAPRO did not use human epidermal growth factor receptor 2 (Her-2/neu) status of breast cancer. Here, we incorporate Her-2/neu in BRCAPRO and validate all the markers. We trained the enhanced model on 406 germline tested individuals, and validated on a separate clinical cohort of 796 individuals for whom test results and family history are available. For model-building, we estimated joint probabilities of ER, PR, and Her-2/neu status for carriers and non-carriers of BRCA1/2 mutations. For validation, we obtained BRCAPRO predictions with and without markers. We calculated area under the receiver operating characteristic curve (AUC), sensitivity, specificity, predictive values, and correct reclassification rates. The AUC for predicting BRCA1 status among individuals who are carriers of at least one mutation improved when ER and PR were used. The AUC for predicting the presence of either mutation improved when Her-2/neu was added. Use of markers also produced highly significant correct reclassification improvements in both cases. Breast tumor markers are useful for prediction of BRCA1/2 mutation status. ER and PR improve discrimination between BRCA1 and BRCA2 mutation carriers while Her-2/neu helps discriminate between carriers and non-carriers, particularly among women who are ER positive and Her-2/neu negative. These results support the use of the enhanced version of BRCAPRO in clinical settings.

KW - BayesMendel

KW - BRCA1

KW - BRCA2

KW - BRCAPRO

KW - CancerGene

KW - ER

KW - Genetic risk

KW - Her-2/neu

KW - PR

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=84860324524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860324524&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-1958-z

DO - 10.1007/s10549-012-1958-z

M3 - Article

VL - 133

SP - 347

EP - 355

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -